← back to search

Jo Caers

Clinique Saint-Joseph · BE
Area of research
Hematology · Oncology
Research interest
Research interests include Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Cancer Treatment and Pharmacology, and Chronic Lymphocytic Leukemia Research.
h-index
40
citations
12,151
works
233
NIH funding
primary concept
Medicine
email

Recent publications

Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study
The Lancet Haematology 2025cited by 72position: middledoi
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
The Lancet Oncology 2023cited by 168position: middledoi
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study
The Lancet Oncology 2023cited by 24position: middledoi
Extramedullary disease in multiple myeloma: a systematic literature review
Blood Cancer Journal 2022cited by 268position: middledoi
Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1
Blood 2022cited by 41position: middledoi
Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations
British Journal of Haematology 2021cited by 171position: middledoi
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage
Blood Cancer Journal 2021cited by 167position: middledoi
MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents
Journal of Hematology & Oncology 2020cited by 169position: lastdoi
The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index
Leukemia 2020cited by 22position: middledoi
Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel
Journal of Hematology & Oncology 2018cited by 318position: firstdoi
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when
Haematologica 2018cited by 149position: firstdoi
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network
Leukemia 2018cited by 99position: middledoi
Pretreatment Health-Related Quality of Life Profile According to the EORTC QLQ-C30 in Patients with Myelodysplastic Syndromes (MDS): Analysis on 443 Lower-Risk MDS Patients
Blood 2018cited by 2position: middledoi
Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group
Blood Cancer Journal 2017cited by 173position: middledoi
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
Blood 2016cited by 928position: middledoi
Central nervous system involvement by multiple myeloma: A multi‐institutional retrospective study of 172 patients in daily clinical practice
American Journal of Hematology 2016cited by 137position: middledoi
Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients
Leukemia & lymphoma/Leukemia and lymphoma 2016cited by 41position: middledoi
Findings of Whole Body Computed Tomography Compared to Conventional Skeletal Survey in Patients with Monoclonal Plasma Cell Disorders - a Study of the International Myeloma Working Group
Blood 2016cited by 16position: middledoi
Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group
Leukemia 2015cited by 254position: middledoi
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
The Lancet Oncology 2014cited by 4,825position: middledoi
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
Leukemia 2012cited by 380position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Evangelos Terpos · Frontier Science Foundation-Hellas4 papers (2016–2018)Hartmut Goldschmidt · Virginia Cooperative Extension4 papers (2016–2018)Brian G.M. Durie · International Myeloma Foundation3 papers (2016–2017)Heinz Ludwig · Comprehensive Cancer Center Vienna3 papers (2018–2020)Joan Bladé · Amyloidosis Foundation3 papers (2016–2022)Meletios Α. Dimopoulos · Korea University3 papers (2016–2018)Niels Abildgaard · Universitetshospitalernes Center for Sundhedsfaglig Forskning3 papers (2016–2018)Jens Hillengaß · Roswell Park Comprehensive Cancer Center3 papers (2016–2017)Philippe Moreau · CEA Cadarache3 papers (2016–2022)Saad Z. Usmani · Weill Cornell Medicine2 papers (2016–2022)Laura Rosiñol · Josep Carreras Leukaemia Research Institute2 papers (2018–2022)Hermann Einsele · Ovarian Cancer Research Alliance2 papers (2016–2018)Kosei Matsue · Akita University2 papers (2016–2017)Torben Plesner · University of Southern Denmark2 papers (2016–2017)Suzanne Lentzsch · Columbia University Irving Medical Center2 papers (2016–2017)Niels W.C.J. van de Donk · National Cancer Center2 papers (2016–2018)Vassilis Koutoulidis · National and Kapodistrian University of Athens2 papers (2016–2017)Lia A. Moulopoulos · National and Kapodistrian University of Athens2 papers (2016–2017) · 2 papers (2016–2017) · 2 papers (2016–2017)